Marker Therapeutics, Inc. Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma Data selected for oral presentation during a plenary session…
Read More
Marker Therapeutics, Inc. Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma Data selected for oral presentation during a plenary session…